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Athletic	 Trainers’	 Knowledge	 and	 Treatment	 of	 Athletes	 with	 Paroxysmal	
Dystonia/Dyskinesia	Chad	Rairdonϯ;	Brian	Dykhuizen	MS,	AT,	ATCϯ;	Erika	Smith-Goodwin	PhD,	AT,	ATCϯ;	Paul	Sparling	MEd,	AT,	ATC€	ϮWilmington	College;		€Cincinnati	Bengals	_________________________________________________________________________________________________________________
BACKGROUND	 	 	 	Paroxysmal	 Dystonia/Dyskinesia	 as	 defined	in	 the	 journal	 Movement	 Disorders	 is	 “A	movement	 disorder	 characterized	 by	sustained	 or	 intermittent	 muscle	contractions,	 causing	 abnormal,	 often	repetitive,	movements,	 posture	 or	 both.”1(13)	Typically	 Paroxysmal	 dystonia	 involves	 a	genetic	mutation.	The	most	predominant	are	Proline-Rich	 Transmembrane	 Protein	 2	(PRRT2),	Myofibrillogenesis	Regulator	1	(MR-1),	 Glucose	 Transporter	 1	 (SLC2A1),	 and	ECHS-1.	 PRRT2	 is	 the	 highest	 occurring	mutation	which	is	around	74.8%	according	to	Paroxysmal	Dyskinesias	Revisited:	 A	Review	of	 500	 Genetically	 Proven	 Cases	 and	 a	 New	Classification.2(1109)	PRRT2	gene	mutation	has	an	onset	of	puberty	and	the	episodes	usually	tend	to	decline	as	the	patient	becomes	older,	eventually	 resolving	 sporadically.2(1111)	 The	function	of	this	protein	is	unknown,	although	it	is	thought	to	be	involved	in	signaling	in	the	brain.3	 The	 MR-1	 gene	 seems	 to	 be	 an	indication	 on	 PNKD.	 About	 one	 third	 of	patients	 have	 reported	 that	 the	 attack	 has	started	 in	 one	 limb,	 but	 could	 eventually	become	generalized.2	In	addition;	MR-1	gene	mutations	seem	to	have	certain	triggers	which	are	 coffee,	 tea	 and/or	 alcohol.2SLC2A1	provides	instructions	for	producing	a	protein	called	the	glucose	transporter	protein	type	1	(GLUT1).	The	GLUT1	protein	is	embedded	in	the	outer	membrane	surrounding	cells,	where			
		 	 	 	 	 	 					it	transports	glucose	into	cells	from	the	blood	or	from	other	cells	for	use	as	fuel.4	The	GLUT1	protein	 also	 transports	 glucose	 between	 the	glial	 cells	 in	 the	 brain,	 which	 protect	 and	maintain	 the	 neurons.4Different	 types	 of	Paroxysmal	 Dystonia	 are	 Paroxysmal	Kinesigenic	Dystonia	(PKD),	Paroxysmal	non-kinesigenic	 Dystonia	 (PNKD).	 And	Paroxysmal	Exercise	Induced	Dystonia	(PED).	PKD	is	triggered	by	rapid	movement	and	“the	attacks	are	brief,	lasting	seconds.”5(1160)	PED	is	defined	 as	 “not	 brought	 on	 by	 sudden	movements	 but	 by	 physical	 exhaustion	 after	continuous	exertion.”5(1161)	The	most	common	treatment	for	paroxysmal	dystonia	is	putting	the	 patient	 on	 some	 type	 of	 antiepileptic;	usually	Carbamazepine.		
OBJECTIVE	 	 	 	 	 	The	 purpose	 of	 this	 study	was	 to	 determine	Certified	Athletic	Trainers	(ATC)	awareness	of	Paroxysmal	Dystonia	(PxD).	PxD	is	defined	as	an	 episodic	 movement	 disorder	 in	 which	abnormal	movements	are	present	only	during	attacks.		
DESIGN	and	SETTING		 	 	 	This	 study	 used	 a	 survey	 research	 design	conducted	at	a	DIII	college	in	Ohio.	
	PARTICIPANTS	 	 	 	 	The	 return	 rate	 was	 62%	 (n=26)	 with	 a	convenience	 sample	 target	 population	 of	N=42.	50%	(n=13)	of	the	population	males			
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were	 and	 50%	 (n=13)	 were	 females.	 50%	(n=13)	 were	 between	 the	 ages	 of	 22-30,	15.4%	 (n=4)	 were	 between	 the	 ages	 31-40,	15.4%	 (n=4)	 were	 between	 the	 ages	 41-50,	51-60	(n=4)	15.4%,	and	61+	(n=1)	3.8%.	The	subjects	 years	 in	 the	 athletic	 training	profession	were	1-5	(n=11)	42.3%,	6-10	(n=4)	15.4%,	11-15	(n=3)	11.5%,	16-20	(n=2)	7.7%,	20+	(n=6)	23.1%.			
INTERVENTIONS	 	 	 	 	The	 research	 was	 approved	 by	 the	 College	Institutional	 Review	 Board.	 Content	 validity	was	 established	 through	 the	 Table	 of	Specification	 (ToS).	 Face	 Validity	 was	established	 through	 a	 panel	 of	 experts.	Descriptive	 statistics	 (percentages	 and	frequencies)	 were	 used	 for	 all	 applicable	items.	Chi-square	test	was	used	for	gender	as	a	grouping	variable.	Kruskal-	Wallis	 test	was	used	for	the	age	and	years	in	profession	as	a	grouping	variable.	There	was	no	 statistically	significant	data.	SPSS	24.0	was	used	to	analyze	the	data.		
MAIN	OUTCOME	MEASUREMENTS		 	The	survey	asked	16	questions.	Questions	2-5,	7,	 8,	 10-13	 used	 a	 5-point	 Likert	 scale.	(Strongly	Agree5,	Agree4,	Neutral3,	Disagree	2,	Strongly	 Disagree1),	Question	 1	 used	 a	 two-point	Likert	scale	(No2,	Yes1)	Question	6	used	a	 4-point	 Likert	 scale	 (Doctorate4,	 Masters3,	Bachelor2,	Associates1).	Question	9	used	a	4-point	 Likert	 scale	 (High	 School4,	 Collegiate3,	Professional	 Teams2,	 Other1).	 Question	 14	used	a	2-point	Likert	 scale	 (Male2,	 Female1).	Question	15	used	a	5-point	Likert	scale	 (22-305,	 31-404,	 41-503,	 51-602,	 61+1).	 Question	16	used	a	5-point	Likert	scale	(1-55,	6-104,	11-153,	16-202,	20+1.)		
RESULTS	 	 	 	 	 	The	population	in	the	study	was	50%	(n=13)	males	and	50%	(n=13)	females.	The	majority	of	 subjects	 had	 at	 least	 1-10	 years	 of	experience	 57.7%	 (n=15).	 65%	 of	 the	
population	 was	 between	 the	 ages	 of	 22-40.	96.2%	 (n=25)	 of	 the	 subjects	 said	 the	disagreed	on	seeing	and	treating	a	case	of	PxD.	85%	 (n=22)	 of	 the	 subjects	 said	 they	 were	curious	to	do	research	on	PxD.		88%	(n=21)	of	subjects	said	they	couldn’t	describe	PxD	and	they	 couldn’t	 help	 the	 patient	 with	 more	knowledge.	 Only	 8%	 (n=2)	 of	 subjects	disagreed	that	PxD	needs	to	be	known	at	any	clinical	 setting.	 0%	 (n=0)	 said	 that	 they	 felt	confident	in	their	ability	to	recognize	the	signs	and	symptoms	of	PxD.	The	subjects	curiosity	to	 increase	 their	 knowledge	 and	 go	 through	research	to	find	out	more	about	PxD	was	85%	(n=22).	11.5%	(n=3)	responded	that	they	did	not	 believe	 that	 they	 as	 a	 clinician	 could	adequately	 treat	 a	 patient	 with	 PxD.	 There	was	no	statistically	significant	data.			
LIMITATIONS	 	 	 	Limitations	of	my	study	 include	 sample	 size,	having	 a	 15	week	 semester	 to	 complete	 the	initial	 research,	 questions	 that	 could	 have	been	 more	 direct	 and	 worded	 more	appropriately.		
CONCLUSION		 	 	 	 	Although	 PxD	 is	 a	 rare	 condition,	 it	 is	satisfying	as	an	AT	to	help	an	athlete	who	has	an	 undiagnosed	 medical	 condition.	 By	monitoring	 the	 chief	 complaints	 (CC)	 and	referring	 you	 will	 appropriately	 help	 the	athlete.	 Do	 not	 dismiss	 the	 patient	 and	 the	unusual	grouping	of	signs	and	symptoms	they	may	present.	PxD	is	another	condition	that	we	can	 add	 to	 our	 ever	 expanding	 knowledge.	There	 is	 always	 something	new	and	exciting	out	 there	and	 that	 is	why	we,	 as	ATs	 should	have	a	passion	to	continue	learning.		
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